3 results
To compare the recurrence rate of tumor at 12 months following IMAGE1 S* assisted TURB (Arm A) with White Light Imaging only assisted TURB (Arm B) in patients with primary or recurrent non-muscle-invasive urothelial bladder cancer (NMIBC Ta/T1/CIS…
Quizartinib selectively inhibits survival pathways that block apoptosis by inhibiting FLT3. Quizartinib inhibits proliferation of FLT3-dependent cell lines, and is effective in human leukemia tumor xenograft models of AML. Data from the Phase 1 and…
To evaluate the long-term safety and tolerability of elsubrutinib and upadacitinib given alone or as the ABBV-599 (elsubrutinib/upadacitinib) combination in SLE subjects who have completed the M19-130 Phase 2 study.